BRIEF—C4XD sells remaining interests in addiction med

C4X Discovery (C4XD) has sold its remaining rights to the oral Orexin-1 receptor antagonist, C4X_3256, to fellow British firm Indivior, for $20 million.

Also known as INDV-2000, Indivior has been developing the Orexin-1 antagonist since 2018, under the terms of an  exclusive global license agreement.

The latest payment means that C4XD will no longer be eligible to receive potential milestone payments of up to $284 million, nor royalties on eventual sales.

C4XD has divested the asset as part of a strategy to focus more on immuno-inflammatory therapeutics, including its lead small molecule, an α4β7 integrin inhibitor under development for inflammatory bowel disease.

Indivior chief scientific officer Christian Heidbreder said the acquisition was “aligned with our goal to build a strong and balanced pipeline focused on addiction treatments.”